CAmpto-CISplatine Plus Radiotherapy in Advanced Cervix Cancer : Search of Tolerated Maximum Dose of Campto
- Sponsor
- ARCAGY/ GINECO GROUP
- Study ID
- NCT00251888
- Phase
- PHASE1
- Status
- Completed
Conditions
- Cervix Cancer
Eligibility Criteria
- Sex
- FEMALE
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- campto (irinotecan) — DRUG
- cisplatin (cisplatyl) — DRUG
Study Details
Search of maximum tolerated irinotecan dose in association with cisplatin and pelvic radiotherapy in patients with an advanced cervix cancer.
Key Dates
- Start date
- Nov 30, 2002
- Status verified
- Feb 2011
- Completion
- Nov 30, 2005
Study Design
- Enrollment
- 15 participants
- Allocation
- NON_RANDOMIZED
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Primary Outcome Measure
To determine the maximum tolerated dose of irinotecan associated with cisplatin and combinated with pelvic radiotherapy in patients with an advanced cervix cancer
Related Studies
- Glutaminase Inhibition and Chemoradiation in Advanced Cervical CancerPHASE2 · Not Yet Recruiting · Washington University School of Medicine · St Louis, Missouri
- Physical Activity Intervention Among Older Women With Gynecologic Cancers (Fit4Treatment)Recruiting · Northwestern University · Chicago, Illinois
- A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.PHASE1 · Recruiting · OncoNano Medicine, Inc. · Los Angeles, California
- Study of Pembrolizumab and Lenvatinib in Metastatic and Recurrent Cervix Cancer (LenPem Cervix)PHASE2 · Recruiting · University of Texas Southwestern Medical Center · Dallas, Texas